Insmed Aktie
WKN: A1JJA3 ISIN: US4576693075
aktueller Kurs:
28,20 EUR
Veränderung:
-0,70 EUR
Veränderung in %:
-2,42 %
weitere Analysen einblenden

Insmed to Host R&D Day on September 30, 2020

Mittwoch, 16.09.20 14:05
Kursticker auf einer digitalen Anzeige.
Bildquelle: pixabay


PR Newswire





BRIDGEWATER, N.J., Sept. 16, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an R&D Day on Wednesday, September 30, 2020. The event is scheduled to take place from 10:00 a.m. to 12:30 p.m. ET in a virtual format.

The agenda will include an overview of recent developments for the Company's pipeline candidates treprostinil palmitil and brensocatib, as well as label expansion efforts and global advancement updates for ARIKAYCE®(amikacin liposome inhalation suspension).

The program will also feature a presentation by Ronald J. Oudiz, M.D., FACP, FACC, FCCP. Dr. Oudiz is a Professor of Medicine at the David Geffen School of Medicine at UCLA, the Interim Chief, Division of Cardiology, and a Director at the Liu Center for Pulmonary Hypertension Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

The call and accompanying slides will be webcast live on the company's website at https://investor.insmed.com/events. To listen to the conference call live, please dial (888) 317-6003 (domestic) or (412) 317-6061 (international) and reference conference ID number 0587949.

A replay of the conference call will be accessible approximately one hour after its completion through October 14, 2020 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing replay access code 10147009. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at https://investor.insmed.com/events.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed is also advancing brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:

Investors:

Argot Partners

Laura Perry or Heather Savelle

(212) 600-1902

insmed@argotpartners.com 

Media:

Mandy Fahey

Senior Director, Corporate Communications

Insmed

(732) 718-3621

amanda.fahey@insmed.com 

(PRNewsfoto/Insmed Incorporated)







Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-rd-day-on-september-30-2020-301131791.html

SOURCE Insmed Incorporated





Quelle: PR Newswire




Hier geht's zur Aktien-Startseite

News und Analysen

Insmed to Host R&D Day on September 30, 2020

PR NewswireBRIDGEWATER, N.J., Sept. 16, 2020BRIDGEWATER, N.J., Sept. 16, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | ►

Volltextsuche

Im Fokus

Aktueller Chart
  • +370% Kursgewinn seit Jahresstart!
  • Explodiert die Tesla-Aktie wieder?
  • Jetzt gratis Tesla-Report downloaden!

Nachrichtensuche

Value oder Growth? Eine Frage so alt wie die Börse

Value oder Growth? Eine Frage so alt wie die Börse
Die Frage, ob es sinnvoller ist, auf Value- oder auf Growth-Titel zu setzen, ist beinahe so alt wie die Börse selbst. Dabei sind mit der Bezeichnung „Value“ bewährte Unternehmen gemeint, deren Buchwert idealerweise aktuell möglichst niedrig bewertet wird.
© 1994-2020 by boerse.de - Quelle für Kurse und Daten: ARIVA.DE AG - boerse.de übernimmt keine Gewähr